Abstract
Background: Phosphodiesterase-5 (PDE5) inhibitors demonstrate off-label anticancer properties, acting through a variety of mechanisms that ultimately reduce tumor proliferation.
Method: Combining PDE5 inhibitors with other anti-oncotic agents further enhances their effectiveness against tumors. Mechanistically, PDE5 inhibitors have been shown to inhibit ATP binding cassette (ABC) transporter protein activity, potentiate reactive oxygen species (ROS) activity, decrease FADD-like IL-1β-converting enzyme (FLICE)- inhibitory protein (c-FLIP) expression, increase blood-brain tumor barrier (BTB) permeability, and, when administered as a combination therapy, sensitize tumors to platinum.
Conclusion: This review offers insights into the various mechanisms by which PDE5 inhibitors exert their antineoplastic actions.
Keywords: ABC transporter, anticancer therapy, antineoplastic agents, phosphodiesterase inhibitors, reactive oxygen species, sildenafil, Viagra®.
Current Cancer Therapy Reviews
Title:PDE5 Inhibitors Offer Novel Mechanisms in Combination and Solo Cancer Therapy
Volume: 13 Issue: 2
Author(s): Robert W. Lyday , Abigail M. Etters, Chris Kim, Fernando Magana, Gabriel M. Pontipiedra, Naveen K.M. Singh and Samuel Kadavakollu *
Affiliation:
- Department of Biomedical Sciences, Burrell College of Osteopathic Medicine, Las Cruces, NM 88001,United States
Keywords: ABC transporter, anticancer therapy, antineoplastic agents, phosphodiesterase inhibitors, reactive oxygen species, sildenafil, Viagra®.
Abstract: Background: Phosphodiesterase-5 (PDE5) inhibitors demonstrate off-label anticancer properties, acting through a variety of mechanisms that ultimately reduce tumor proliferation.
Method: Combining PDE5 inhibitors with other anti-oncotic agents further enhances their effectiveness against tumors. Mechanistically, PDE5 inhibitors have been shown to inhibit ATP binding cassette (ABC) transporter protein activity, potentiate reactive oxygen species (ROS) activity, decrease FADD-like IL-1β-converting enzyme (FLICE)- inhibitory protein (c-FLIP) expression, increase blood-brain tumor barrier (BTB) permeability, and, when administered as a combination therapy, sensitize tumors to platinum.
Conclusion: This review offers insights into the various mechanisms by which PDE5 inhibitors exert their antineoplastic actions.
Export Options
About this article
Cite this article as:
Lyday W. Robert , Etters M. Abigail , Kim Chris , Magana Fernando, Pontipiedra M. Gabriel , Singh K.M. Naveen and Kadavakollu Samuel *, PDE5 Inhibitors Offer Novel Mechanisms in Combination and Solo Cancer Therapy, Current Cancer Therapy Reviews 2017; 13 (2) . https://dx.doi.org/10.2174/1573394713666170731152749
DOI https://dx.doi.org/10.2174/1573394713666170731152749 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rock1 & 2 Perform Overlapping and Unique Roles in Angiogenesis and Angiosarcoma Tumor Progression
Current Molecular Medicine Endogenous Factors in the Recovery of Reproductive Function After Testicular Injury and Cancer
Current Molecular Medicine Nature and Nurture in the Early-Life Origins of Metabolic Syndrome
Current Pharmaceutical Biotechnology Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology Treatment of PSA only Recurrence of Prostate Cancer After Prior Local Therapy
Current Pharmaceutical Design Clostridium ljungdahlii: A Review of the Development of an Industrial Biocatalyst
Current Biotechnology Peptidyl Prolyl Isomerase, Pin1 is a Potential Target for Enhancing the Therapeutic Efficacy of Etoposide
Current Cancer Drug Targets Concomitant Drug Treatment and Elimination in the RCC-affected Kidneys: Can We Kill Two Birds with One Stone?
Current Drug Metabolism A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets In Vitro Antitumoral Activity of Palladium(II) and Platinum(II) Complexes with O,O'-Dialkyl Esters of Ethylene-bis(S)-Leucine
Letters in Drug Design & Discovery Stem Cell Niche in Tissue Homeostasis, Aging and Cancer
Current Medicinal Chemistry Estrogen-Induced Genetic Alterations and Their Role in Carcinogenicity
Current Genomics Bladder Cancer: A Simple Model Becomes Complex
Current Genomics Antibiotics as Inhibitor of Glutathione S-transferase: Biological Evaluation and Molecular Structure Studies
Current Drug Metabolism New Prognostic Markers and Potential Therapeutic Targets in Human Testicular Germ Cell Tumors
Current Medicinal Chemistry Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design Colchicine: An Old Wine in a New Bottle?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The GNAS Locus: Quintessential Complex Gene Encoding Gsα, XLαs, and other Imprinted Transcripts
Current Genomics Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry Muscarinic Acetylcholine Receptors: Relevance to Infertility and Male Contraception
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)